research use only
Cat.No.S7205
| Related Targets | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Other MDM2/MDMX Inhibitors | Nutlin-3 Nutlin-3a RG-7112 Brigimadlin SAR405838 NSC 207895 NVP-CGM097 Siremadlin (HDM201) Nutlin-3b MX69 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| SJSA1 cells | Cytotoxic assay | Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as growth inhibition by MTT assay, IC50=0.01 μM | 23808545 | |||
| HCT116 cells | Cytotoxic assay | Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as growth inhibition by MTT assay, IC50=0.01 μM | 23808545 | |||
| SJSA1 cells | Proliferation assay | 1 h | Antiproliferative activity against human SJSA1 cells assessed as inhibition of EdU incorporation after 1 hr by Click-iT EdU HCS assay in presence of 10% human serum, IC50=0.045 μM | 24456472 | ||
| SJSA1 cells | Cytotoxic assay | 16 h | Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 16 hrs by EdU incorporation assay in presence of 10% human serum, IC50=0.045 μM | 24601644 | ||
| RKO cells | Cytotoxic assay | Cytotoxicity against human RKO cells expressing wild type p53 assessed as growth inhibition by MTT assay, IC50=0.07 μM | 23808545 | |||
| MDA-MB-435 cells | Cytotoxic assay | Cytotoxicity against human MDA-MB-435 cells expressing p53 mutant assessed as growth inhibition by MTT assay, IC50=9.1 μM | 23808545 | |||
| SW480 cells | Cytotoxic assay | Cytotoxicity against human SW480 cells expressing p53 mutant assessed as growth inhibition by MTT assay, IC50=13.3 μM | 23808545 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(162.21 mM)
Ethanol : 8 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 616.48 | Formula | C31H29Cl2F2N3O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1229705-06-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F | ||
| Targets/IC50/Ki |
p53-MDM2 interaction
(Cell-free assay) 6 nM
|
|---|---|
| In vitro |
Idasanutlin (RG7388) inhibits cell proliferation with IC50 of 30 nM, and induces dose-dependent p53 stabilization, cell cycle arrest, as well as cell apoptosis in cancer cells expressing wild-type p53.
|
| Kinase Assay |
Biochemical Binding Affinity – HTRF Assay
|
|
The p53-MDM2 HTRF assay is performed in buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM DTT, 0.02 or 0.2 mg/ml BSA. Idasanutlin (RG7388) is stored in aliquots as a 10 mM stock solution in DMSO at 4°C in 96-deep-well plates. It is thawed and mixed immediately prior to testing. The compound is incubated with GST-MDM2 and a biotinylated p53 peptide for one hour at 37°C. Phycolink goat anti-GST (Type 1) allophycocyanin and Eu-8044-streptavidin are then added and followed by one hour incubation at room temperature. Plates are read using the Envision fluorescence reader. IC50 values are determined from inter-plate duplicate or triplicate sets of data. Data are analyzed by XLfit4 (Microsoft) using a 4 Parameter Logistic Model (Sigmoidal Dose-Response Model) and the equation Y= (A+ ((B-A)/ (1+ ((C/x)^D)))), where A and B are enzyme activity in the absence or presence of infinite inhibitor compound, respectively, C is the IC50 and D is the Hill coefficient.
|
|
| In vivo |
In a mouse SJSA human osteosarcoma xenograft model, Idasanutlin (RG7388) (25 mg/kg p.o.) causes tumor growth inhibition and regression. In a SJSA xenograft model, it results in induction of apoptosis and antiproliferation.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p53 / MDM2 / Puma / Bax / Bak / Noxa / c-PARP-1 p21 EZH1 / H3K27me3 |
|
29232553 |
| Immunofluorescence | E-cadherin |
|
25671108 |
| Growth inhibition assay | Cell viability Cell proliferation |
|
29857559 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05952687 | Withdrawn | Rhabdoid Tumor|Atypical Teratoid/Rhabdoid Tumor|Atypical Teratoid/Rhabdoid Tumor of CNS|CNS Tumor |
St. Jude Children''s Research Hospital |
March 2024 | Phase 1 |
| NCT03287245 | Terminated | Polycythemia Vera |
Hoffmann-La Roche |
February 21 2018 | Phase 2 |
| NCT03362723 | Completed | Solid Tumors |
Hoffmann-La Roche |
November 27 2017 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.